Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$15.56
+1.2%
$13.32
$9.57
$30.41
$2.15B0.891.51 million shs1.54 million shs
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.54
+1.1%
$0.44
$0.16
$0.75
$574.57M0.04932,256 shs470,200 shs
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$45.88
-3.1%
$45.63
$1.16
$14.10
$1.99B-0.12189,291 shs345,633 shs
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
$17.31
+1.8%
$18.32
$14.06
$27.29
$1.90B0.01641,002 shs539,457 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+1.59%-5.65%+16.00%-20.07%-38.22%
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
+0.53%+4.35%+26.26%+8.83%+212.14%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00%-4.66%+4.29%-11.51%+38.19%
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
-3.41%-12.09%-2.91%-13.70%-9.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.7837 of 5 stars
3.32.00.03.43.52.50.0
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
2.4314 of 5 stars
3.51.00.00.02.25.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.67
Moderate Buy$42.13170.73% Upside
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00
N/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
3.00
Buy$43.00148.41% Upside

Current Analyst Ratings Breakdown

Latest ELTP, ARWR, GMTX, and NAMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
5/13/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$21.00 ➝ $17.00
5/13/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
5/8/2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$42.00 ➝ $40.00
4/8/2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
3/3/2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$41.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$545.21M3.94N/AN/A$1.54 per share10.10
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
$56.62M10.15$0.03 per share16.94$0.03 per share17.93
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
$47.14M40.33N/AN/A$3.50 per share4.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$599.49M-$1.40N/AN/AN/AN/A-236.60%-64.09%8/14/2025 (Estimated)
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
$20.11M-$0.02N/AN/A-25.70%-6.92%-3.94%6/30/2025 (Estimated)
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
-$176.94M-$1.88N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)

Latest ELTP, ARWR, GMTX, and NAMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q2 2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million
5/8/2025Q1 2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
7.27
6.09
6.09
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
0.12
3.27
1.90
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
N/A
10.61
10.61

Institutional Ownership

CompanyInstitutional Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
62.61%
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
0.01%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
75.42%
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
89.89%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
400138.10 million120.68 millionOptionable
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
401.07 billion914.31 millionNot Optionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
4109.82 million74.37 millionOptionable

Recent News About These Companies

Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.00

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.56 +0.19 (+1.24%)
Closing price 04:00 PM Eastern
Extended Trading
$15.83 +0.27 (+1.74%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Elite Pharmaceuticals stock logo

Elite Pharmaceuticals OTCMKTS:ELTP

$0.54 +0.01 (+1.05%)
As of 03:58 PM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$45.88 -1.49 (-3.15%)
As of 05/27/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$17.31 +0.30 (+1.76%)
Closing price 04:00 PM Eastern
Extended Trading
$17.31 0.00 (-0.01%)
As of 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.